VRTX | tickerfilter.com

Fundamental analysis

69%

Profitability 95%

Dept financing 7%

Liquidity 64%

Performance 60%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.84%

1 Month

21.35%

3 Months

-1.05%

6 Months

2.98%

1 Year

17.38%

2 Year

60.21%

Key data

Stock price

$488.44

P/E Ratio

0.00

DAY RANGE

$481.70 - $491.80

EPS

$9.51

52 WEEK RANGE

$377.85 - $519.88

52 WEEK CHANGE

$15.45

MARKET CAP

120.038 B

YIELD

N/A

SHARES OUTSTANDING

258.102 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.31

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,797,610

AVERAGE 30 VOLUME

$1,648,182

Company detail

CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.

VRTX - VERTEX PHARMACEUTICALS INC / MA